Dr. Timothy Fan, a professor at the University of Illinois, has been named one of eight semifinalists for the inaugural Canine Health Discovery of the Year Award presented by the American Kennel Club Canine Health Foundation (AKC CHF). The recognition, announced Oct. 14, highlights a translational research program centered on intratumoral cytokine therapy that advanced from engineered proteins at the Massachusetts Institute of Technology to clinical protocols and peer‑reviewed publications involving naturally occurring cancers in dogs and early human clinical data. Coverage from Dailyillini has highlighted this story.

The semifinalist nod places Fan and his collaborators in a competitive field the foundation created to spotlight discoveries that bridge veterinary and human medicine and accelerate new treatment options. Coverage of the nomination appeared on the University of Illinois College of Veterinary Medicine site on Oct. 22 and in the Daily Illini on Nov. 7, underscoring the institutional pride attached to the work and the wider interest in research that directly impacts patient care across species.

Fan’s approach focuses on delivering cytokines — proteins produced by immune cells that amplify immune responses — directly into tumors. As Fan explained: “Cytokines are proteins that are released by your immune cells, and their principal function is to increase your immune cell activity.” By administering those proteins locally, the team aims to boost an anti‑tumor immune response in the tumor microenvironment while avoiding the systemic toxicity that can occur with high systemic doses. Reporting by Illinois Edu offers additional detail on this case.

The therapeutic cytokines used in the program were engineered in collaboration with colleagues at MIT. Contributions from engineer Dane Wittrup and others at MIT included developing the modified protein constructs used in the trials; those engineered cytokines were then incorporated into preclinical and clinical protocols executed with University of Illinois investigators and clinicians. The nomination materials cited a sequence of peer‑reviewed publications and clinical milestones that together established preclinical and early clinical credibility for the intratumoral cytokine approach.

Chronologically, the translational arc is clear in the published record: dog studies describing safety and positive outcomes in patients with naturally occurring cancers were published in March 2023, and human phase‑one data reporting supportive findings appeared in September 2023. Those publications, plus the laboratory and clinical work that underpinned them, were singled out in the foundation’s announcement and in the university’s summary of the nomination.

Graduate student Matheus Moreno Passos Barbosa of the University of Illinois contributed to both laboratory investigations and clinical efforts that supported the published studies and the subsequent nomination, reflecting the team nature of the program. Fan has emphasized that the work is a collaborative effort spanning basic protein engineering to clinical application: the engineered cytokines from MIT were integrated into protocols at the University of Illinois, and veterinary patients provided an important translational bridge to human testing. As covered by Akcchf, readers can explore more context around the event.

University and foundation leaders framed the semifinalist selection as institutional and cross‑disciplinary validation. “The University of Illinois should be really proud that he’s a faculty member,” said Dr. Stephanie Montgomery, CEO of the American Kennel Club Canine Health Foundation, citing the nomination as a signal that the work is leading the way forward. Montgomery added that the nominated therapy offers “new hope for people who have dogs with cancer,” highlighting the dual benefit of veterinary advances that also inform human medicine. Dr. Anne Barger, head of the Department of Veterinary Clinical Medicine at the University of Illinois, noted: “The impact that he’s having on not only patients, but people as well, is incredible.” These observations reflect how the foundation and university view the project as a model of translational science.

Fan acknowledged the competition ahead in the award process but emphasized the team effort behind the science. “Certainly it would be great to get to the Final Four and then the finals, but you know, there’s a lot of competition there,” he said, while noting that the nomination itself is recognition of the laboratory, clinical, and institutional contributions that made the work possible. The semifinalist selection, the nomination materials state, rests on a combination of peer‑reviewed evidence, clinical milestones, and the demonstration that the approach can be applied safely and effectively in canine patients — a necessary step for any therapy intended to translate to human clinical practice.

The AKC CHF award was designed to elevate discoveries that improve canine health and inform human medicine, offering visibility and support for promising translational projects. Being named one of eight semifinalists not only recognizes the science but can also help attract attention and resources that may accelerate further testing and broader clinical implementation. For Fan’s team, the recognition underscores a research pipeline that moved engineered cytokines from an MIT laboratory to University of Illinois clinics and into the published literature describing outcomes in both dogs and people.

As the semifinals move forward, the nomination places Fan’s work into the running for an award intended to celebrate breakthroughs that both advance veterinary care and contribute to human oncology. Whether or not the team reaches the Final Four, the semifinalist designation documents a notable sequence of translational milestones: engineered cytokines developed in collaboration with MIT, dog studies published in March 2023 demonstrating safety and efficacy in naturally occurring cancers, and human phase‑one data reported in September 2023 supporting the approach’s clinical promise. The acknowledgment from the AKC Canine Health Foundation thus serves as a public affirmation of a cross‑institutional effort to turn benchside protein engineering into bedside — and kennel‑side — therapeutic options.

Source

Original reporting: view the original article.